Company Information

  

Address: 11388 SORRENTO VALLEY ROAD  
City: SAN DIEGO 
State: CA 
Zip Code: 92121-1345 
Telephone: (858) 794-8889 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. We are seeking to translate our unique knowledge of the tumor microenvironment to create therapies that have the potential to improve cancer patient survival. Our research primarily focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-0.92NAN/E
03/2017-0.91NAN/E
12/2016-0.81NAN/E
09/2016-0.55NAN/E
06/2016-0.52NAN/E
03/2016-0.29NAN/E
12/2015-0.25NAN/E
09/2015-0.33NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.19Total Liab/Total Assets1.12
Net Inc/Total Assets-0.39Total Liab/Inv Cap1.55
Net Inc/Inv Cap-0.54Total Liab/Comm Equity0.53
Pretax Inc/Net Sales-0.69Interest Coverage Ratio-4.10
Net Inc/Net Sales-0.70Curr Debt/Equity-0.54
Cash Flow/Net Sales-0.34LTD/Equity-6.13
SG&A/NetSales0.31Total Debt/Equity-6.67
Asset Utilization   Liquidity  
Net Receivables Turnover6.10Quick Ratio4.43
Inventory Turnover2.75Current Ratio4.70
Inventory Day Sales0.01Net Rec/Curr Assets0.06
Net Sales/Work Cap0.73Inv/Curr Assets0.06
Net Sales/PP&E34.40  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 33.75 29.57 39.00 31.85
Cost of Goods Sold 7.79 7.54 8.00 9.13
Selling & Admin Exps 13.10 12.62 12.23 11.60
Operating Income -25.48 -27.53 -22.58 -22.74
Interest Exp 5.54 5.45 5.60 5.25
Pretax Income -30.58 -32.69 -27.81 -27.66
Other Income 0.44 0.29 0.37 0.33
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -30.76 -32.90 -27.39 -28.95

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 297.53 178.99 204.98 221.05
Receivables - Total 14.47 12.45 15.68 17.68
Inventories - Total 15.17 14.29 14.62 12.85
Total Current Assets 340.83 222.35 256.53 272.61
Net Property, Plant & Equipment 3.33 3.74 4.26 4.41
Total Assets 344.79 226.77 261.52 282.50
Liabilities        
Accounts Payable 32.58 28.01 32.40 30.37
Debt in Current Liabilities 45.52 29.60 17.39 12.39
Total Current Liabilities 82.62 61.71 54.59 52.66
Long-Term Debt 165.52 184.43 199.23 199.80
Total Liabilities 286.62 285.27 294.00 294.49
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.14 0.13 0.13 0.13
Retained Earnings -649.00 -618.24 -585.34 -557.96
Treasury Stock NA NA NA NA
Total Stockholders' Equity 58.17 -58.50 -32.48 -11.99
Total Liabilities and Stockholders' Equity 344.79 226.77 261.52 282.50

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -17.00 -22.46 -15.77 -8.75
Net Cash Provided by Investing Activities -49.29 4.27 21.05 8.25
Net Cash Provided by Financing Activities 135.85 -3.38 0.28 0.48

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201242.32-53.55-0.48
12/201354.80-83.48-0.74
12/201475.33-68.38-0.56
12/2015135.06-32.23-0.25
12/2016146.69-103.02-0.81
Growth Rates36.44----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17184121,73185.78




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.